# Compare the Evidence, Not the Hype

> Compare Four Research Records — Research Peptide Fundamentals — Right Peptides — Research Peptide Fundamentals research peptides compared by model, mechanism, endpoint, evidence maturity, status, and central caution.

**CLAIM DESK / COMPARISON MATRIX**

KPV, semaglutide, CJC-1295, and NAD+ aligned by what they are, what was measured, and how far each conclusion can travel.

## The short version

These four records do not form a treatment ladder. They concern different molecules, pathways, research questions, and evidence levels. KPV is a tripeptide studied mainly in cells and animals for inflammatory signaling [1][2][3][4]. Semaglutide is a modified peptide medicine with large randomized human outcome trials [9][10][11]. CJC-1295 is a GHRH analogue with small human pharmacology studies showing sustained GH/IGF-1 stimulation [15][16][17]. NAD+ is a coenzyme, not a peptide, and oral human research mainly concerns its precursors NMN and NR [18][19][20][22].

The most reliable comparison therefore asks three questions: What model generated the result? What endpoint changed? What source defines the boundary? A molecular mechanism may be well established even when a health benefit is not. A blood marker may move without changing a clinical outcome. A large trial may establish one outcome only in a defined population. The matrix below keeps those distinctions in view and supplies no personal-use recommendation.

## The claim-checking matrix

| Dimension | KPV | Semaglutide | CJC-1295 | NAD+ |
| --- | --- | --- | --- | --- |
| What it is | Melanocortin-derived tripeptide | Modified GLP-1 peptide agonist | Modified GHRH peptide analogue | Dinucleotide coenzyme; not a peptide |
| Main pathway | PepT1 uptake; inflammatory signaling | GLP-1 receptor signaling | GHRH receptor to GH/IGF-1 axis | Redox metabolism; sirtuins, PARPs, CD38 |
| Main cited models | Cells, mice, rabbits, reviews [1][2][3][4][6] | Large randomized human trials and safety review [9][10][11][12] | Small studies in healthy adults and analytical chemistry [14][15][16][17] | Human precursor trials and reviews [18][19][20][21][22] |
| Typical endpoint | Cytokines, colitis severity, wound closure | Body-weight change, kidney and cardiovascular events | GH, IGF-1, serum protein signals | Blood NAD+, insulin sensitivity, walking or quality-of-life measures |
| Evidence maturity | Preclinical | Mature clinical | Early human pharmacology | Mechanistically mature; clinical translation limited |
| Central caution | No established human efficacy or safety | Known tolerability issues and population-specific interpretation | Biological activity is not proven therapeutic benefit | Biomarker change is not longevity evidence |

## Mechanism: four different questions

KPV asks whether a small alpha-MSH-derived fragment can modulate inflammatory pathways without pigmentary action. Its PepT1 transport and suppression of NF-kB and MAP-kinase signaling are supported in intestinal cells and mouse models [3][5]. Semaglutide asks what follows from long-acting GLP-1 receptor activation across metabolic and appetite circuits; outcome trials then test whether the mechanism translates to clinical events [9][10][11].

CJC-1295 asks whether albumin-linked GHRH signaling can sustain stimulation of the GH/IGF-1 axis while retaining natural pulses. Small studies answer that pharmacology question affirmatively [16][17]. NAD+ research asks whether replenishing a central cellular coenzyme through precursors changes metabolism or function. The basic coenzyme biology is strong [21], while human translation remains mixed [18]. The mechanisms are not comparable on a single scale; each frames a different hypothesis.

## Evidence maturity: count the steps

Evidence maturity is not captured by whether a result is “positive.” KPV has several coherent preclinical findings, including targeted-delivery experiments [1][2]. The missing step is controlled human testing. CJC-1295 crosses that boundary only narrowly: small human studies demonstrate hormonal and proteomic changes [15][16][17], but they do not establish broad clinical benefits or long-term safety.

NAD+ precursor trials include randomized human designs and useful endpoints [19][20][22], yet the literature asks many questions at once and often measures intermediate markers. A recent synthesis finds limited efficacy and sparse tissue data [18]. Semaglutide has traveled furthest through the chain, from mechanism to large trials measuring body weight and major cardiovascular or kidney events [9][10][11]. Even there, evidence remains endpoint- and population-specific. Mature evidence means more links in the chain have been tested, not that uncertainty disappears.

## How to read an endpoint

An endpoint is the exact result investigators chose to measure. In KPV studies, endpoints include inflammatory signaling, cytokines, experimental disease severity, and tissue repair [1][3][6]. In CJC-1295 studies, the principal endpoints are hormone levels, pulse patterns, and serum protein changes [15][16][17]. In NAD+ precursor work, endpoints range from blood NAD+ to muscle insulin sensitivity and walking distance [19][20][22]. Semaglutide trials include body-weight change and prespecified cardiovascular or kidney composites [9][10][11].

The endpoint determines the permissible sentence. Lower inflammatory signaling supports “modulated an inflammatory pathway,” not “treated human inflammatory disease.” Higher IGF-1 supports “activated the axis,” not “improved recovery.” Higher blood NAD+ supports “raised the measured pool,” not “slowed aging.” Fewer major clinical events in a defined randomized population supports a clinical outcomes claim for that population.

## Safety and status are part of the comparison

Semaglutide is an approved prescription medicine with a developed safety literature; gastrointestinal intolerance and biliary disease are established parts of its record, while some low-incidence signals remain unresolved [12]. KPV and CJC-1295 are not approved human medicines. KPV lacks human clinical safety data, while CJC-1295 has only limited early human studies. Unknown does not mean harmless, and it does not mean proven dangerous; it means the uncertainty must be stated.

NAD+ has a different regulatory and quality landscape because oral supplements, precursors, and compounded intravenous products are not interchangeable. Short precursor trials provide some tolerability data [19][22], but they cannot settle every formulation or long-term population. Across all four records, product identity and study equivalence matter. A published result for a defined molecule and preparation does not validate material of uncertain composition.

## The useful conclusion

The comparison does not produce a winner. It produces a calibrated map. KPV has an interesting preclinical anti-inflammatory program. Semaglutide has a mature clinical outcomes record with known limitations. CJC-1295 has demonstrated human endocrine activity without established broad benefit. NAD+ has foundational biology and measurable precursor effects, while human clinical meaning remains unsettled.

That is the purpose of the Right Peptides frame: preserve the distance between mechanism, marker, and outcome. The individual pages provide the detail; the [reference desk](/references) provides the source trail.

---

Right Peptides is an independent claim-checking digest that keeps each peptide conclusion attached to its model, endpoint, and source—not a shop or medical service.